Duloxetine Capsule, Delayed Release
Product Images NDC 47335-381

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 47335-381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-duloxetine-figure1 (Spl Duloxetine Figure1)

A Kaplan-Meier curve showing the proportion of patients experiencing relapse over time in days, comparing treatment groups of Placebo and Duloxetine. The graph indicates lower relapse rates with Duloxetine compared to Placebo over approximately 200 days.*

FDA Label Image

Spl Duloxetine Figure10

A line graph comparing the percentage of patients improved versus percentage improvement in pain from baseline for Duloxetine 60 mg/120 mg once daily and placebo. The x-axis shows percentage improvement in pain from >0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Data points illustrate trends for both treatments over the range of pain improvement scores.*

FDA Label Image

Spl-duloxetine-figure2 (Spl Duloxetine Figure2)

A line graph depicting the proportion of patients with relapse over time from randomization to relapse (days), comparing treatment groups with Duloxetine and placebo. The graph shows the proportion of relapse on the vertical axis and time in days on the horizontal axis, with separate lines representing Duloxetine and placebo groups.*

FDA Label Image

Spl-duloxetine-figure3 (Spl Duloxetine Figure3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline comparing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo groups. The graph illustrates trends in patient improvement across different pain improvement thresholds.*

FDA Label Image

Spl-duloxetine-figure4 (Spl Duloxetine Figure4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The graph shows three separate curves comparing these treatments across a range of pain improvement percentages from 0 to 100.*

FDA Label Image

Spl-duloxetine-figure5 (Spl Duloxetine Figure5)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily, Duloxetine 60 mg once daily, and a placebo, showing patient improvement trends across different pain improvement percentages.*

FDA Label Image

Spl-duloxetine-figure6 (Spl Duloxetine Figure6)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 120 mg, 60 mg, and 20 mg once daily doses with placebo, showing patient improvement percentages across different pain improvement thresholds from greater than 0% up to 100%.*

FDA Label Image

Spl Duloxetine Figure8

A line graph comparing the percentage of patients improved over various levels of percent improvement in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The graph plots pain improvement percentages on the x-axis and the percentage of patients improved on the y-axis, showing higher improvement with Duloxetine across most measured ranges.*

FDA Label Image

Spl Duloxetine Figure9

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows a higher percentage of patient improvement across the range compared to placebo.*

FDA Label Image

Spl-duloxetine-lable-20mg (Spl Duloxetine Lable 20mg)

Duloxetine Delayed-Release Capsules USP 20 mg label by Sun Pharmaceutical Industries, Inc., for a 60-capsule package. Label includes dispensing instructions for pharmacists, a barcode, and an image of an olive green capsule imprinted with '381' on each side.*

FDA Label Image

Spl-duloxetine-lable-30mg (Spl Duloxetine Lable 30mg)

Label for Duloxetine Delayed-Release Capsules USP, 30 mg strength, oral capsule dosage form. The label indicates a quantity of 30 capsules and includes a barcode. It features a blue and gray capsule image with imprint '382' and the Sun Pharmaceutical Industries, Inc. logo. Directions for the pharmacist to dispense with medication guide are present.*

FDA Label Image

Spl-duloxetine-lable-60mg (Spl Duloxetine Lable 60mg)

Label for Duloxetine Delayed-Release Capsules USP 60 mg from Sun Pharmaceutical Industries, Inc. The label notes each delayed-release capsule contains 67.3 mg of duloxetine hydrochloride USP equivalent to 60 mg duloxetine. The package contains 30 capsules and is intended for oral use. Storage instructions and lot/expiration placeholders are also visible.*

FDA Label Image

Spl-duloxetine-structure (Spl Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, showing its molecular composition with a thiophene ring, a naphthalene moiety, and an amine group associated with a hydrochloride ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.